Corporativo Fragua S.A.B. de C.V

—

What it is

Farmacias Guadalajara was founded in March 1942 in Guadalajara, Jalisco, by Francisco Arroyo Verduzco, who began selling patented medicines and household products. The listed holding company, Corporativo Fragua, pools those stores together with logistics, real-estate, and support businesses under one roof.

Every store runs on the “SuperFarmacia” concept, combining in one building a pharmacy, a convenience store, and a supermarket. Three distribution centres and a delivery fleet that covers 50 million kilometres a year keep those shelves stocked around the clock.

Who owns it

Corporativo Fragua has been publicly traded on the Mexican Stock Exchange since October 1997, when it placed roughly 20% of its capital; ownership remains heavily influenced by the founding family, descendants of Francisco Arroyo Verduzco, who hold key positions to ensure continuity. Institutional investors hold about 7.8% of shares (our calculation from EODHD data), leaving the Arroyo family in firm control of the free float.

Who runs it

Javier Arroyo Chávez chairs the board of directors and serves as CEO of Corporativo Fragua. The executive committee is led by Javier Arroyo Navarro as general director, with María Fernanda García Orozco as finance director and Francisco Arroyo Jiménez as operations director.

The board of seven includes Guillermina Arroyo Chávez as vice-chair, with multiple family representatives — Francisco Arroyo Jiménez, Patricia Arroyo Navarro, and Rodrigo Arroyo Jiménez — alongside independent directors. This is an old-fashioned family compact dressed in modern listed-company clothes.

The money, in plain words

Sales grew from MXN 97.9bn (US$5.65bn) in 2022 to MXN 120.2bn (US$6.94bn) in 2024 — a 22.8% rise over two years (our calculation). Yet the business keeps only about 3.4 pesos of profit from every 100 pesos of sales — a net margin of 3.41% — which is typical and acceptable for a high-volume, low-price pharmacy retailer.

For every peso that shareholders own, the company earns about 16 back each year — a return on equity of 16.45%, healthy for retail. The balance sheet carries MXN 6.04bn (US$348.8m) in cash and no reported financial debt (our calculation), which means the expansion programme is self-funded — a conservative strength that also explains why the stock trades at only 9.4 times earnings, a price-to-earnings ratio modest enough to catch a value investor’s eye.

What it is doing now

For the twenty-eighth consecutive year, Fragua beat its own store-opening target: by December 2025, it had 3,009 locations — 142 new SuperFarmacias added in the year — reaching 505 cities across all 32 Mexican states, including 20 cities where it had no presence before.

A mobile app launched in early 2025 lets customers browse, order, and track deliveries, adding a digital layer to a chain whose competitive edge has always been geography and hours, not technology. Corporativo Fragua ranks 47th in Expansión’s 2025 list of Mexico’s 500 most important companies.

What to watch

• Margin pressure. In the fourth quarter of 2025, net profit fell 21.1% year-on-year, hurt by pricing strategy, rising labour costs, and higher financing costs. Watch whether operating leverage from new stores offsets these headwinds in 2026.
• Pace of expansion. Opening 120–140 stores a year is capital-intensive; the no-debt balance sheet gives room, but any slowdown in same-store sales — which grew 6.5% in 2025 — would test that discipline.
• Succession and governance. The family-centric approach combines long-term strategic oversight with professional management practices, but the depth of that professional layer matters as the business scales past 3,000 units.
• Competition. Farmacias del Ahorro operates over 1,800 stores; Farmacias Benavides runs 1,045 units in 190 cities. Fragua leads in scale; rivals are closing the gap on service.

—

This is news, not investment advice.